Literature DB >> 20237094

Identification of pathogenic rare yeast species in clinical samples: comparison between phenotypical and molecular methods.

Emilio Cendejas-Bueno1, Alicia Gomez-Lopez, Emilia Mellado, Juan L Rodriguez-Tudela, Manuel Cuenca-Estrella.   

Abstract

Species identification using both phenotypic and molecular methods and antifungal susceptibility tests was carried out with 60 uncommon clinical yeasts. Our data show that phenotypic methods were insufficient for correct identification (only 25%) and that most of the wrongly identified strains showed a resistant antifungal profile.

Entities:  

Mesh：

Year:  2010        PMID： 20237094      PMCID： PMC2863878          DOI： 10.1128/JCM.00336-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  19 in total

1.  Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus.

Authors:  Julia Alcoba-Flórez; Sebastián Méndez-Alvarez; Josep Cano; Josep Guarro; Eduardo Pérez-Roth; María del Pilar Arévalo
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

2.  In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003.

Authors:  Manuel Cuenca-Estrella; Dolores Rodriguez; Benito Almirante; Juliette Morgan; Ana Maria Planes; Manel Almela; José Mensa; Ferran Sanchez; Josefina Ayats; Montserrat Gimenez; Margarita Salvado; David W Warnock; Albert Pahissa; Juan L Rodriguez-Tudela
Journal:  J Antimicrob Chemother       Date:  2004-12-23       Impact factor: 5.790

3.  Candida ciferrii, a new fluconazole-resistant yeast causing systemic mycosis in immunocompromised patients.

Authors:  E Gunsilius; C Lass-Flörl; C M Kähler; G Gastl; A L Petzer
Journal:  Ann Hematol       Date:  2001-03       Impact factor: 3.673

4.  Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III.

Authors:  Arianna Tavanti; Amanda D Davidson; Neil A R Gow; Martin C J Maiden; Frank C Odds
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

5.  Candida bracarensis sp. nov., a novel anamorphic yeast species phenotypically similar to Candida glabrata.

Authors:  Alexandra Correia; Paula Sampaio; Steve James; Célia Pais
Journal:  Int J Syst Evol Microbiol       Date:  2006-01       Impact factor: 2.747

6.  Comparison of use of phenotypic and genotypic characteristics for identification of species of the anamorph genus Candida and related teleomorph yeast species.

Authors:  G N Latouche; H M Daniel; O C Lee; T G Mitchell; T C Sorrell; W Meyer
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

7.  Kodamaea (Pichia) ohmeri fungemia in a pediatric patient admitted in a public hospital.

Authors:  Jadson Duque De Barros; Suerda Maria Nogueira Do Nascimento; Fernanda Janaína Silva De Araújo; Regina De Fátima Dos Santos Braz; Vania Sousa Andrade; Bart Theelen; Teun Boekhout; Maria Teresa Illnait-Zaragozi; Maria Narriman Guimarães Gouveia; Maria Conceição Fernandes; Maria Goretti Lins Monteiro; Maria Tereza Barreto De Oliveira
Journal:  Med Mycol       Date:  2009-11       Impact factor: 4.076

8.  Rapid identification of pathogenic fungi directly from cultures by using multiplex PCR.

Authors:  Guizhen Luo; Thomas G Mitchell
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

9.  Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy.

Authors:  Arnaldo Lopes Colombo; Analy S Azevedo Melo; Robert F Crespo Rosas; Reinaldo Salomão; Marcelo Briones; Richard J Hollis; Shawn A Messer; Michael A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  2003-08       Impact factor: 2.803

10.  Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Maria J Buitrago; Araceli Monzon; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191
View more
  20 in total

1.  Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.

Authors:  M Cuenca-Estrella; A Gomez-Lopez; I Cuesta; O Zaragoza; E Mellado; J L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 2.  Are the Conventional Commercial Yeast Identification Methods Still Helpful in the Era of New Clinical Microbiology Diagnostics? A Meta-Analysis of Their Accuracy.

Authors:  Brunella Posteraro; Ljupcho Efremov; Emanuele Leoncini; Rosarita Amore; Patrizia Posteraro; Walter Ricciardi; Maurizio Sanguinetti
Journal:  J Clin Microbiol       Date:  2015-05-20       Impact factor: 5.948

3.  Molecular identification of closely related Candida species using two ribosomal intergenic spacer fingerprinting methods.

Authors:  Muriel Cornet; Boualem Sendid; Chantal Fradin; Claude Gaillardin; Daniel Poulain; Huu-Vang Nguyen
Journal:  J Mol Diagn       Date:  2010-12-23       Impact factor: 5.568

4.  Characterization of a new clinical yeast species, Candida tunisiensis sp. nov., isolated from a strain collection from Tunisian hospitals.

Authors:  Jamel Eddouzi; Valérie Hofstetter; Marizeth Groenewald; Mohamed Manai; Dominique Sanglard
Journal:  J Clin Microbiol       Date:  2012-10-17       Impact factor: 5.948

5.  Species identification of invasive yeasts including Candida in Pakistan: limitations of phenotypic methods.

Authors:  Joveria Farooqi; Kauser Jabeen; Noureen Saeed; Afia Zafar; Mary Eleanor Brandt; Rumina Hasan
Journal:  J Pak Med Assoc       Date:  2012-10       Impact factor: 0.781

6.  Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme.

Authors:  Michael A Pfaller; Leah N Woosley; Shawn A Messer; Ronald N Jones; Mariana Castanheira
Journal:  Mycopathologia       Date:  2012-05-13       Impact factor: 2.574

7.  Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts.

Authors:  E Cendejas-Bueno; A Kolecka; A Alastruey-Izquierdo; B Theelen; M Groenewald; M Kostrzewa; M Cuenca-Estrella; A Gómez-López; T Boekhout
Journal:  J Clin Microbiol       Date:  2012-09-05       Impact factor: 5.948

8.  Genetic diversity of medically important and emerging Candida species causing invasive infection.

Authors:  Karina Bellinghausen Merseguel; Angela Satie Nishikaku; Anderson Messias Rodrigues; Ana Carolina Padovan; Renata Carmona e Ferreira; Analy Salles de Azevedo Melo; Marcelo Ribeiro da Silva Briones; Arnaldo Lopes Colombo
Journal:  BMC Infect Dis       Date:  2015-02-13       Impact factor: 3.090

9.  Analysis of strain relatedness using high resolution melting in a case of recurrent candiduria.

Authors:  Sara Gago; Belen Lorenzo; Alicia Gomez-Lopez; Isabel Cuesta; Manuel Cuenca-Estrella; Maria J Buitrago
Journal:  BMC Microbiol       Date:  2013-01-23       Impact factor: 3.605

10.  Application of MALDI-TOF MS for requalification of a Candida clinical isolates culture collection.

Authors:  Reginaldo Lima-Neto; Cledir Santos; Nelson Lima; Paula Sampaio; Célia Pais; Rejane P Neves
Journal:  Braz J Microbiol       Date:  2014-08-29       Impact factor: 2.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.